[The assessment of TIKLO efficacy in patients with intermittent claudication].
The efficacy of TIKLO was compared with acetylsalicylic acid in treatment of patients with intermittent claudication. Patients were divided into 2 groups (30 and 33 subjects). The first group received TIKLO (250 mg, BID), the second one - Thrombo ASS (100 mg, QD). Outcome measures included platelet aggregation, walking distance and the time of ankle-brachial index (ABI) recovery after treadmill test. TIKLO was shown to reduce platelet aggregation, increase pain-free walking distance and decrease the time of ABI recovery after treadmill test. TIKLO administration was accompanied with minimal adverse events.
Zatevakhin
I I
II
Zolkin
V N
VN
Shiller
E E
EE
D000368:Aged; D050197:Atherosclerosis / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D005080:Exercise Test; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D035002:Lower Extremity / Q000098:blood supply / Q000503:physiopathology; D008297:Male; D009069:Movement Disorders / Q000453:epidemiology / Q000209:etiology; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine